Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499546 | 0.86 | TSHR (0.56) | TSHRRIPK2ALDH1A1LMNANPC1 | |
| SCHEMBL2862025 | 0.84 | TSHR (0.55) | TSHRRIPK2ALDH1A1LMNANPC1 | |
| SCHEMBL27472808 | 0.81 | TSHR (0.52) | TSHRRIPK2LMNANPC1MAPK14 | |
| SCHEMBL2078386 | 0.80 | TSHR (0.51) | TSHRMAPK14 | |
| SCHEMBL17604081 | 0.80 | TSHR (0.51) | TSHRRIPK2ALDH1A1LMNANPC1 | |
| SCHEMBL1717058 | 0.80 | TSHR (0.58) | TSHRRIPK2ALDH1A1LMNANPC1 | |
| SCHEMBL174541 | 0.77 | TSHR (0.76) | TSHRRIPK2ALDH1A1LMNANPC1 | |
| SCHEMBL2076997 | 0.76 | TSHR (0.54) | TSHRRIPK2ALDH1A1LMNANPC1 | |
| SCHEMBL1717082 | 0.76 | TSHR (0.54) | TSHRRIPK2ALDH1A1LMNANPC1 | |
| SCHEMBL2077100 | 0.76 | TSHR (0.54) | TSHRRIPK2ALDH1A1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | TSHR 2618/4885RIPK2 132/4885ALDH1A1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.